
Mark C Walters MD
Professor of Pediatrics, UCSF and Jordan Family Director, BMT Program, UCSF Benioff Children's Hosp, Oakland
Join to view full profile
747 52nd StDept Of Hematology/OncologyOakland, CA 94609
Phone+1 510-428-3374
Fax+1 510-601-3916
Dr. Walters is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Mark Walters is a Pediatric Hematologist & Oncologist who is chief of pediatric hematology at UCSF School of Medicine. He completed his medical training at the University of California San Diego School of Medicine, followed by a fellowship in Pediatric Hematology/Oncology at the University of Washington. His expertise includes hemoglobinopathies, thalassemias, hematopoietic stem cell transplantation, bone marrow transplantation, and sickle-cell anemia. He is involved in several clinical trials, including those focused on sickle cell disease and gene editing/gene therapy. Dr. Walters has authored multiple publications in reputable journals such as NEJM, NEJM Evidence, Lancet, and Blood Advances, with his work being cited by other publications numerous times.
Education & Training
University of WashingtonFellowship, Pediatric Hematology/Oncology, 1988 - 1992
University of California San Diego School of MedicineClass of 1985
Certifications & Licensure
CA State Medical License 1999 - 2027
NV State Medical License 2007 - 2023
KY State Medical License 2007 - 2021
MA State Medical License 2007 - 2020
RI State Medical License 2009 - 2020
NJ State Medical License 2007 - 2019
PA State Medical License 2007 - 2010
American Board of Pediatrics Pediatric Hematology-Oncology- Join now to see all
Clinical Trials
Publications & Presentations
PubMed
- Reduced-Intensity Haploidentical Bone Marrow Transplantation in Children with Severe Sickle Cell Disease: BMT CTN 1507.Mark C Walters, Adetola A Kassim, Mary Eapen, Lori C Jordan, Sumit Pruthi
Blood Advances. 2026-10-28 - 6 citationsGene Therapy for Sickle Cell Disease: Practice Recommendations from the American Society for Transplantation and Cellular Therapy and the International Society for Cel...Akshay Sharma, Adetola Kassim, Alexis Thompson, David A Williams, Hien D Liu
Transplantation and Cellular Therapy. 2026-07-01 - 1 citationsCure Sickle Cell Initiative recommendations on common data elements for sickle cell disease gene therapy trials.Sophie Lanzkron, Victoria H Coleman-Cowger, Alexis A Thompson, C Patrick Carroll, Traci Clemons
Blood Advances. 2026-06-09
Journal Articles
- The Safety and Efficacy of Clofarabine in Combination with High-Dose Cytarabine and Total Body Irradiation Myeloablative Conditioning and Allogeneic Stem Cell Transpla...Stacey Zahler, Mitchell S Cairo, Jennifer Krajewski, M Fevzi Ozkaynak, Alexandra C Cheerva, Theodore B Moore, Alfred P Gillio, Mark C Walters, Nature
Abstracts/Posters
- Northstar-2: Updated Safety and Efficacy Analysis of Lentiglobin Gene Therapy in Patients with Transfusion-Dependent _-Thalassemia and Non-_0/_0 GenotypesMark C. Walters, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- The Relationships between Target Gene Transduction, Engraftment of HSCs and RBC Physiology in Sickle Cell Disease Gene TherapyMark C. Walters, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Preliminary Results of a Phase 1/2 Clinical Study of Zinc Finger Nuclease-Mediated Editing of BCL11A in Autologous Hematopoietic Stem Cells for Transfusion-Dependent B...Mark C. Walters, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Advancing Science in Sickle Cell Disease: Implications for the Future of Care61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Significantly Improved Long Term Health Related Quality of Life (HRQL) and Neurocognition Following Familial Haploidentical Stem Cell Transplantation (HISCT) Utilizing...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Honoring Dr. John Zaia: A Legacy of Science, Leadership, and KindnessFebruary 27th, 2025
VUMC Part of New Study Validating Curative Therapy for Sickle Cell DiseaseFebruary 27th, 2025
Novel Gene Therapy Trial for Sickle Cell Disease LaunchesNovember 22nd, 2024
Grant Support
- NRSA Training CoreUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2023–2028
- Hematopoietic Cell Therapy For Young Adults With Severe Sickle Cell DiseaseNational Heart, Lung, And Blood Institute2011
- Northern California Consortium For Sickle Cell DiseaseNational Heart, Lung, And Blood Institute2006–2008
- Induction Of Stable Chimerism For Sickle Cell AnemiaNational Heart, Lung, And Blood Institute2001–2004
- Mechanisms Of Globin Gene SilencingNational Heart, Lung, And Blood Institute1998–1999
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
